Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aldeyra Therapeutics, Inc.ALDX · Entity 6839 | Chief Financial Officer | March 30, 2022 | April 01, 2022 |
| Alkermes plc.ALKS · Entity 2392 | SVP, Chief Financial Officer | October 08, 2026 | October 09, 2026 |
| Omega Therapeutics, Inc.OMGA · Entity 83618 | Chief Financial Officer | February 07, 2024 | February 09, 2024 |
| Scholar Rock Holding CorpSRRK · Entity 3721 | Director | July 01, 2026 | July 06, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aldeyra Therapeutics, Inc.
Report date March 30, 2022 · Filed April 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 274,825 |
Reported balance
After 2022-03-30 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2022-03-30 · Grant · Acquired 93,322 · Balance 274,825 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2: Includes 8,022 shares previously purchased under the Issuer's Employee Stock Purchase Plan. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.52 · Expires 2032-03-29 | Direct | 250,000 |
Reported balance
After 2022-03-30 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2022-03-30 · Grant · Acquired 250,000 · Balance 250,000 F3: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date.
F2: Includes 8,022 shares previously purchased under the Issuer's Employee Stock Purchase Plan.
F3: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022.
Alkermes plc.
Report date October 08, 2026 · Filed October 09, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 5,095 |
Ending reported balance
After 2026-10-08 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-08 · Exercise / conversion · Acquired 9,164 · Balance 9,164 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. Row 2 · 2026-10-08 · Tax withholding · Disposed 4,069 · Balance 5,095 |
| Restricted Stock Unit AwardSEC Table II · derivative / convertible security | Direct | 27,492 |
Reported balance
After 2026-10-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-10-08 · Exercise / conversion · Disposed 9,164 · Balance 27,492 F1: Each restricted stock unit represents a contingent right to receive one ordinary share. F2: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 10/8/2026. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit represents a contingent right to receive one ordinary share.
F2: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 10/8/2026.
Omega Therapeutics, Inc.
Report date February 07, 2024 · Filed February 09, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2034-02-06 | Direct | 110,000 |
Reported balance
After 2024-02-07 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-02-07 · Grant · Acquired 110,000 · Balance 110,000 F1: The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date.
Scholar Rock Holding Corp
Report date July 01, 2026 · Filed July 06, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 20,466 |
Reported balance
After 2026-07-01 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-07-01 · Sale · Disposed 2,105 · Balance 20,466 F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 21, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.050 to $54.030, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3: Consists of 13,627 shares of common stock and 6,839 RSUs. |
| Common StockSEC Table I · non-derivative | Direct | 19,518 |
Reported balance
After 2026-07-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-07-01 · Sale · Disposed 948 · Balance 19,518 F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 21, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.040 to $54.795, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5: Consists of 12,679 shares of common stock and 6,839 RSUs. |
Filing footnotes · ownership attribution and instrument terms
F1: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 21, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs).
F2: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.050 to $54.030, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F3: Consists of 13,627 shares of common stock and 6,839 RSUs.
F4: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.040 to $54.795, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
F5: Consists of 12,679 shares of common stock and 6,839 RSUs.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 08, 2026 Filed Oct 9, 2026 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionRestricted Stock Unit Award · Derivative | 9,164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000131 · form4.xml · derivative · entry 3 Reed Joshua · CIK 0001746541 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,492 Underlying: Ordinary Shares · 9,164 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. F2 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 10/8/2026. F2 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 10/8/2026. Read SEC document |
| October 08, 2026 Filed Oct 9, 2026 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | Tax withholdingOrdinary Shares | 4,069 | $40.11 | $163,207.59 |
DisclosureSEC source: 0001520262-26-000131 · form4.xml · nonDerivative · entry 2 Reed Joshua · CIK 0001746541 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,095 Read SEC document |
| October 08, 2026 Filed Oct 9, 2026 22:18 UTC | Alkermes plc. ALKS · Entity 2392 | Exercise / conversionOrdinary Shares | 9,164 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001520262-26-000131 · form4.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,164 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one ordinary share. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 948 | $54.28 | $51,458.77 |
DisclosureSEC source: 0001193125-26-296247 · ownership.xml · nonDerivative · entry 2 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,518 F1 · shares: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 21, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $54.040 to $54.795, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · balance_after: Consists of 12,679 shares of common stock and 6,839 RSUs. Read SEC document |
| July 01, 2026 Filed Jul 6, 2026 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 2,105 | $53.50 | $112,608.66 |
DisclosureSEC source: 0001193125-26-296247 · ownership.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 20,466 F1 · shares: This sale was effected pursuant to a Rule 10b-5-1 trading plan adopted on March 21, 2026 to cover tax obligations upon the vesting and settlement of restricted stock units (RSUs). F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $53.050 to $54.030, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 13,627 shares of common stock and 6,839 RSUs. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:55 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 4,310 | $0.00 Strike: $45.33 | $0.00 |
DisclosureSEC source: 0001104659-26-071430 · tm2617049-6_4seq1.xml · derivative · entry 2 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,310 Underlying: Common Stock · 4,310 shares Expires 2036-06-04 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting, subject to continued service to the Issuer through such date. Read SEC document |
| June 04, 2026 Filed Jun 8, 2026 20:55 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 6,839 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071430 · tm2617049-6_4seq1.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 22,571 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2027 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 15,732 shares of common stock and 6,839 RSUs. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 30,854 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-26-000063 · form4.xml · derivative · entry 2 Reed Joshua · CIK 0001746541 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,854 Underlying: Ordinary Shares · 30,854 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 3/2/2027. Read SEC document |
| March 02, 2026 Filed Mar 5, 2026 01:21 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 66,430 | $0.00 Strike: $30.25 | $0.00 |
DisclosureSEC source: 0001520262-26-000063 · form4.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,430 Underlying: Ordinary Shares · 66,430 shares Expires 2036-03-02 F1 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 3/2/2027. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 20:41 UTC | Alkermes plc. ALKS · Entity 2392 | GrantRestricted Stock Unit Award · Derivative | 36,656 | $0.00 | $0.00 |
DisclosureSEC source: 0001520262-25-000006 · form4.xml · derivative · entry 2 Reed Joshua · CIK 0001746541 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,656 Underlying: Ordinary Shares · 36,656 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one ordinary share. F3 · derivative.exercise_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 10/8/2026. F3 · derivative.expiration_date: Shares subject to the restricted stock unit award vest in four equal annual installments, commencing on 10/8/2026. Read SEC document |
| October 08, 2025 Filed Oct 10, 2025 20:41 UTC | Alkermes plc. ALKS · Entity 2392 | GrantEmployee Stock Option (Right to Buy) · Derivative | 158,743 | $0.00 Strike: $31.51 | $0.00 |
DisclosureSEC source: 0001520262-25-000006 · form4.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 158,743 Underlying: Ordinary Shares · 158,743 shares Expires 2035-10-08 F1 · derivative.exercise_date: Shares underlying the stock option vest and become exercisable in four equal annual installments, commencing on 10/8/2026. Read SEC document |
| May 29, 2025 Filed May 30, 2025 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 500 | $30.04 | $15,021.75 |
DisclosureSEC source: 0001415889-25-015002 · form4-05302025_040506.xml · nonDerivative · entry 2 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,732 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025 to cover tax withholding obligations upon the vesting and settlement of RSUs. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $29.990 to $30.098, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F5 · balance_after: Consists of 8,100 shares of common stock and 7,632 RSUs. Read SEC document |
| May 29, 2025 Filed May 30, 2025 20:30 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | SaleCommon Stock | 4,900 | $29.68 | $145,440.82 |
DisclosureSEC source: 0001415889-25-015002 · form4-05302025_040506.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 16,232 F1 · shares: This sale was effected pursuant to a Rule 10b5-1 trading plan adopted on February 27, 2025 to cover tax withholding obligations upon the vesting and settlement of RSUs. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $28.995 to $29.970, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request. F3 · balance_after: Consists of 8,600 shares of common stock and 7,632 RSUs. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:46 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 9,206 | $0.00 Strike: $30.46 | $0.00 |
DisclosureSEC source: 0001104659-25-052482 · tm2516084-6_4seq1.xml · derivative · entry 2 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,206 Underlying: Common Stock · 9,206 shares Expires 2035-05-22 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| May 22, 2025 Filed May 23, 2025 20:46 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 7,632 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-052482 · tm2516084-6_4seq1.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,132 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2026 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 13,500 shares of Common Stock and 7,632 RSUs. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:31 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 18,000 | $0.00 Strike: $8.36 | $0.00 |
DisclosureSEC source: 0001415889-24-018647 · form4-07012024_090733.xml · derivative · entry 2 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,000 Underlying: Common Stock · 18,000 shares Expires 2034-06-27 F3 · derivative.exercise_date: Options to vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| June 27, 2024 Filed Jul 1, 2024 21:31 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantCommon Stock | 13,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-018647 · form4-07012024_090733.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,500 F1 · shares: Each restricted stock unit ("RSU") represents the contingent right to receive, upon vesting of the RSU, one share of the Issuer's common stock. The shares subject to this RSU vest on the earlier of June 15, 2025 or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. F2 · balance_after: Consists of 13,500 RSUs. Read SEC document |
| February 07, 2024 Filed Feb 9, 2024 16:57 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantStock Option (Right to Buy) · Derivative | 110,000 | $0.00 Strike: $3.59 | $0.00 |
DisclosureSEC source: 0000950170-24-013352 · ownership.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 110,000 Underlying: Common Stock · 110,000 shares Expires 2034-02-06 F1 · derivative.exercise_date: The option vests and becomes exercisable with respect to 25% of the underlying shares on February 7, 2025 and in twelve (12) equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 7, 2028, subject to the Reporting Person's continued service to the Issuer through each such vesting date. Read SEC document |
| June 21, 2023 Filed Jun 22, 2023 23:07 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 36,000 | $0.00 Strike: $9.11 | $0.00 |
DisclosureSEC source: 0001415889-23-010205 · form4-06222023_110607.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,000 Underlying: Common Stock · 36,000 shares Expires 2033-06-21 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or on the date of the Issuer's next Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 16:05 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $6.46 | $0.00 |
DisclosureSEC source: 0000899243-23-006726 · doc4.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2033-02-27 F1 · derivative.exercise_date: The options vest and become exercisable with respect to 25% of the underlying shares on February 28, 2024 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on February 28, 2027, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| October 27, 2022 Filed Oct 28, 2022 18:36 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 55,000 | $0.00 Strike: $5.27 | $0.00 |
DisclosureSEC source: 0000899243-22-034463 · doc4.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 Underlying: Common Stock · 55,000 shares Expires 2032-10-26 F1 · derivative.exercise_date: The options vest and become exercisable as to 25% of the underlying shares on October 27, 2023 and as to 6.25% of the underlying shares upon the Reporting Person's completion of each three full months of continued service to the Issuer thereafter, such that the option will be fully vested and exercisable on October 27, 2026. Read SEC document |
| May 31, 2022 Filed Jun 2, 2022 18:51 UTC | Omega Therapeutics, Inc. OMGA · Entity 83618 | GrantOption (Right to Buy) · Derivative | 320,000 | $0.00 Strike: $2.27 | $0.00 |
DisclosureSEC source: 0000899243-22-020758 · doc4.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,000 Underlying: Common Stock · 320,000 shares Expires 2032-05-30 F1 · derivative.exercise_date: The options vest and become exercisable with respect to 25% of the underlying shares on May 23, 2023 and in equal quarterly installments thereafter such that the option will become fully vested and exercisable on May 23, 2026, subject to the Reporting Person's continued service to the Issuer through each vesting date. Read SEC document |
| May 26, 2022 Filed May 27, 2022 20:35 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Option (Right to Buy) · Derivative | 28,000 | $0.00 Strike: $4.75 | $0.00 |
DisclosureSEC source: 0001104659-22-065955 · tm2216969-7_4seq1.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,000 Underlying: Common Stock · 28,000 shares Expires 2032-05-26 F1 · derivative.exercise_date: This option shall vest and become fully exercisable on the earlier of the first anniversary following the date of grant or the next scheduled Annual Meeting subject to continued service to the Issuer through such date. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 23:37 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $4.52 | $0.00 |
DisclosureSEC source: 0000899243-22-013174 · doc4.xml · derivative · entry 2 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2032-03-29 F3 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2022. Read SEC document |
| March 30, 2022 Filed Apr 1, 2022 23:37 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 93,322 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013174 · doc4.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 274,825 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2022, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. F2 · balance_after: Includes 8,022 shares previously purchased under the Issuer's Employee Stock Purchase Plan. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 23:25 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 150,185 | $0.00 Strike: $11.71 | $0.00 |
DisclosureSEC source: 0000899243-21-015839 · doc4.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,185 Underlying: Common Stock · 150,185 shares Expires 2031-04-11 F1 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2021. Read SEC document |
| March 16, 2021 Filed Mar 18, 2021 21:24 UTC | Scholar Rock Holding Corp SRRK · Entity 3721 | GrantStock Options (Right to Buy) · Derivative | 15,600 | $0.00 Strike: $66.41 | $0.00 |
DisclosureSEC source: 0001179110-21-003595 · edgar.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Sotck · 15,600 shares Expires 2031-03-16 F1 · derivative.exercise_date: This option vests monthly over three (3) years, with the first monthly amount vesting on April 18, 2021, provided Mr. Reed continues to serve on the Board on such vesting date. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:49 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 137,707 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0000899243-20-007067 · doc4.xml · derivative · entry 2 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,707 Underlying: Common Stock · 137,707 shares Expires 2030-03-01 F2 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020. Read SEC document |
| March 02, 2020 Filed Mar 5, 2020 00:49 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007067 · doc4.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,774 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| March 02, 2020 Filed Mar 6, 2020 21:44 UTC Amendment | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $3.78 | $0.00 |
DisclosureSEC source: 0000899243-20-007448 · doc4a.xml · derivative · entry 2 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2030-03-01 F2 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2020. Read SEC document |
| March 02, 2020 Filed Mar 6, 2020 21:44 UTC Amendment | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 137,707 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-20-007448 · doc4a.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 173,481 F1 · acquired: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2020, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| September 05, 2019 Filed Sep 9, 2019 20:38 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | PurchaseCommon Stock | 3,200 | $4.71 | $15,072.00 |
DisclosureSEC source: 0000899243-19-023129 · doc4.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,774 F1 · balance_after: Includes 2,937 shares of common stock acquired under the Issuer's Employee Stock Purchase Plan (ESPP) in 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:24 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 250,000 | $0.00 Strike: $8.05 | $0.00 |
DisclosureSEC source: 0000899243-19-006732 · doc4.xml · derivative · entry 2 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2029-03-04 F2 · derivative.exercise_date: The shares subject to this option shall vest in equal monthly installments over the next 48 months of continuous service to the Issuer after January 1, 2019. Read SEC document |
| March 05, 2019 Filed Mar 7, 2019 22:24 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantCommon Stock | 29,637 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-19-006732 · doc4.xml · nonDerivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,637 F1 · shares: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). The RSU vests ratably in equal annual installments over a four-year period beginning on January 1, 2019, provided that the Reporting Person has provided continuous service to the Issuer through the applicable vesting date. Read SEC document |
| July 30, 2018 Filed Aug 1, 2018 20:46 UTC | Aldeyra Therapeutics, Inc. ALDX · Entity 6839 | GrantEmployee Stock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $6.80 | $0.00 |
DisclosureSEC source: 0000899243-18-020988 · doc4.xml · derivative · entry 1 Reed Joshua · CIK 0001746541 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2028-07-29 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after one year of continuous service to the Issuer. The balance of the shares subject to this option shall vest in equal monthly installments over the next 36 months of continuous service to the Issuer following the vesting commencement date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.